AR078886A1 - Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades - Google Patents

Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades

Info

Publication number
AR078886A1
AR078886A1 ARP100104082A ARP100104082A AR078886A1 AR 078886 A1 AR078886 A1 AR 078886A1 AR P100104082 A ARP100104082 A AR P100104082A AR P100104082 A ARP100104082 A AR P100104082A AR 078886 A1 AR078886 A1 AR 078886A1
Authority
AR
Argentina
Prior art keywords
factor
amino acid
seq
acid residues
machine
Prior art date
Application number
ARP100104082A
Other languages
English (en)
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR078886A1 publication Critical patent/AR078886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
ARP100104082A 2009-11-04 2010-11-04 Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades AR078886A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28046009P 2009-11-04 2009-11-04
US28171609P 2009-11-20 2009-11-20

Publications (1)

Publication Number Publication Date
AR078886A1 true AR078886A1 (es) 2011-12-07

Family

ID=43303899

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100104082A AR078886A1 (es) 2009-11-04 2010-11-04 Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades

Country Status (14)

Country Link
US (1) US20110165648A1 (cg-RX-API-DMAC7.html)
EP (1) EP2496695A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013509866A (cg-RX-API-DMAC7.html)
KR (1) KR20120120153A (cg-RX-API-DMAC7.html)
CN (1) CN102666850A (cg-RX-API-DMAC7.html)
AR (1) AR078886A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012011607A2 (cg-RX-API-DMAC7.html)
CA (1) CA2782481A1 (cg-RX-API-DMAC7.html)
IN (1) IN2012DN03338A (cg-RX-API-DMAC7.html)
MX (1) MX2012005430A (cg-RX-API-DMAC7.html)
RU (1) RU2012122700A (cg-RX-API-DMAC7.html)
TW (1) TW201121993A (cg-RX-API-DMAC7.html)
WO (1) WO2011057014A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201202602B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015035342A2 (en) 2013-09-08 2015-03-12 Oligasis Llc Factor viii zwitterionic polymer conjugates
JP2017515811A (ja) 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体及びその使用法
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016061562A2 (en) 2014-10-17 2016-04-21 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
CN108472382A (zh) 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
AU2016344133A1 (en) * 2015-10-30 2018-05-17 Genentech, Inc. Anti-Factor D antibody formulations
CN108289951A (zh) 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
CA3059938A1 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
KR0185192B1 (ko) 1989-10-05 1999-04-01 제임스 더블유. 데이비 신규의 유전자 및 폴리펩티드의 무세포 합성 및 분리
US5244800A (en) * 1990-04-27 1993-09-14 The Uab Research Foundation Crystals of human complement factor d that are triclinic
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
JP2010508819A (ja) * 2006-11-02 2010-03-25 ジェネンテック インコーポレイテッド ヒト化抗ｄ因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) * 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados

Also Published As

Publication number Publication date
BR112012011607A2 (pt) 2020-06-02
KR20120120153A (ko) 2012-11-01
IN2012DN03338A (cg-RX-API-DMAC7.html) 2015-10-23
JP2013509866A (ja) 2013-03-21
TW201121993A (en) 2011-07-01
RU2012122700A (ru) 2013-12-10
ZA201202602B (en) 2013-06-26
CN102666850A (zh) 2012-09-12
CA2782481A1 (en) 2011-05-12
EP2496695A1 (en) 2012-09-12
WO2011057014A1 (en) 2011-05-12
MX2012005430A (es) 2012-06-19
US20110165648A1 (en) 2011-07-07

Similar Documents

Publication Publication Date Title
AR078886A1 (es) Estructura co-cristalina del factor d y el anticuerpo anti-factor d util pa-ra diagnostico, profilaxis y tratamiento de enfermedades
ES2602971T3 (es) Composición de anticuerpo modificado
Greco et al. Proteomic analyses on an ancient Egyptian cheese and biomolecular evidence of brucellosis
McVeigh et al. Fasciola hepatica virulence-associated cysteine peptidases: a systems biology perspective
CL2008003089A1 (es) Metodo para tratar enfermedad de alzheimer que comprende un regimen de un anticuerpo que se un epitopo en el n-terminal del peptido amiloide beta, anticuerpo humanizado contra la proteina amiloide beta que tiene sustituidas las posiciones 234, 235, y 237 por alanina en la region constante de las cadenas pesadas.
PE20212075A1 (es) PROTEINAS DE FUSION Fc IL-22 Y METODOS DE USO
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
Foldés et al. Results of surgical clitoral repair after ritual excision: 453 cases
HRP20150807T1 (hr) PRIPRAVCI KOJI SADRŽE PROTUTIJELO, ILI NJEGOV FRAGMENT, SPECIFIÄŚNO ZA aP2, NAMIJENJENO UPOTREBI U LIJEÄŚENJU DIJABETESA, NEPODNOŠENJA GLUKOZE ILI OTPORNOSTI NA INZULIN UZROKOVANE PRETILOŠÄ†U
BR112012010252A2 (pt) variantes de glicosilação de anticorpo
JP2016536315A5 (cg-RX-API-DMAC7.html)
O'Shaughnessy et al. Natural history of proximal deep vein thrombosis assessed by duplex ultrasound.
Mizutani et al. Possible action of human placental aminopeptidase N in feto-placental unit.
Parkinson et al. Development of an acid challenge-based in vitro dentin disc occlusion model.
Qiu et al. Fibrin (ogen) olytic activity of bumblebee venom serine protease
Umasuthan et al. Rock bream (Oplegnathus fasciatus) serpin, protease nexin-1: transcriptional analysis and characterization of its antiprotease and anticoagulant activities
Venkateswarlu et al. An all-atom solution-equilibrated model for human extrinsic blood coagulation complex (sTF–VIIa–Xa): a protein–protein docking and molecular dynamics refinement study
Zhang et al. Enzyme activity of Schistosoma japonicum cercarial elastase SjCE-2b ascertained by in vitro refolded recombinant protein
Imamura et al. Identification and partial characterization of a gut Rhipicephalus appendiculatus cystatin
PL405046A1 (pl) Genetycznie kodowany oparty na FRET biosensor aktywności MMP-9 i jego zastosowanie
ATE551067T1 (de) Tumstatin zur behandlung von erkrankungen die mit der neumodellierung von atemwegsgewebe zusammenhängen
Schemczssen-Graeff et al. Description of a serpin toxin in Loxosceles (Brown spider) venoms: cloning, expression in baculovirus-infected insect cells and functional characterization
Saavedra et al. Natural snake venom inhibitors and their pharmaceutical uses: challenges and possibilities
Robbins et al. Macromolecules from living and fossil biominerals: Implications for the establishment of molecular phylogenies
Bafwafwa et al. Risk factors affecting mortality in children with pulmonary tuberculosis in lubumbashi, democratic republic of the Congo

Legal Events

Date Code Title Description
FB Suspension of granting procedure